Scientia Vascular, a provider of neurovascular treatment systems, has received the US Food and Drug Administration (FDA) approval for the Plato 17 and the Socrates 38 catheters.

The Plato 17 is a DMSO-compatible microcatheter and Socrates 38 is an aspiration catheter engineered for treating ischemic stroke.

Specialised in microfabricated guidewires, Scientia has applied the same technologies, design principles, and precision machinery to revolutionise catheter manufacturing.

Scientia Vascular CEO John Lippert said: “Our FDA clearance is a significant milestone for Scientia Vascular. By applying proven microfabrication technology to catheters and designing our access and treatment devices for efficiency when used together, we’re providing physicians the next generation of neurovascular access tools.

“I am immensely grateful to our dedicated teams whose tireless efforts have made this FDA clearance milestone possible. Their commitment to excellence and innovation continues to drive our patient mission forward.”

Socrates 38 aspiration catheter is currently in a limited market release, and Scientia is collecting its valuable feedback and clinical insights.

It is a crucial phase for the company in executing the final stages of the commercial launch of the catheter, bringing better, more advanced options to physicians treating stroke.

The Plato 17 microcatheter represents a step forward in catheter design and provides physicians with control and stability for several neurovascular applications.

Scientia said it aims to enhance patient care through innovative medical devices, focusing on neurovascular advancements, and technological breakthroughs in the medical field.

Scientia Vascular chief commercial officer Paul Fischer said: “We’ve seen what microfabrication can do in products like our Aristotle 24 and Colossus wires in changing the standard of care for patient treatment in stroke, so it’s rewarding to see the excitement and buzz surrounding microfabricated technology in catheters with our physician community.

“We are eager to see how these advanced technologies will enhance patient care and offer new possibilities for physicians treating a variety of neurovascular disease states.”